Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression

Vaccine

Volumn 29, Issue 7, 2011, Pages 1504-1513

  Krupa, Magdalena ^a   Canamero, Marta ^b   Gomez, Carmen E ^a   Najera, Jose L ^a   Gil, Jesus ^c   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Prime boost immunization; Prostate cancer vaccine; TRAMP

Indexed keywords

CANCER VACCINE; MEMBRANE ANTIGEN; MODIFIED VACCINIA VIRUS ANKARA VECTOR; PROSTATE STEM CELL ANTIGEN; PROTEIN STEAP1; RECOMBINANT DNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CONTROLLED STUDY; DISEASE SEVERITY; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HISTOPATHOLOGY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE; CRICETINAE; DNA, RECOMBINANT; GENETIC VECTORS; GPI-LINKED PROTEINS; IMMUNIZATION, SECONDARY; MALE; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; VACCINES, DNA; VACCINIA VIRUS;

EID: 79151473356     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.016     Document Type: Article

References (49)

1. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371(May (9625)):1710-1721.
2. Reiter R.E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998, 95(February (4)):1735-1740.
3. Gu Z., Thomas G., Yamashiro J., Shintaku I.P., Dorey F., Raitano A., et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19(March (10)):1288-1296.
4. Han K.R., Seligson D.B., Liu X., Horvath S., Shintaku P.I., Thomas G.V., et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004, 171(March (3)):1117-1121.
5. Argani P., Rosty C., Reiter R.E., Wilentz R.E., Murugesan S.R., Leach S.D., et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001, 61(June (11)):4320-4324.
6. Elsamman E.M., Fukumori T., Tanimoto S., Nakanishi R., Takahashi M., Toida K., et al. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int 2006, 98(September (3)):668-673.
7. Amara N., Palapattu G.S., Schrage M., Gu Z., Thomas G.V., Dorey F., et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001, 61(June (12)):4660-4665.
8. Dannull J., Diener P.A., Prikler L., Furstenberger G., Cerny T., Schmid U., et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000, 60(October (19)):5522-5528.
9. Kiessling A., Schmitz M., Stevanovic S., Weigle B., Holig K., Fussel M., et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002, 102(December (4)):390-397.
10. Matsueda S., Kobayashi K., Nonaka Y., Noguchi M., Itoh K., Harada M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2004, 53(June (6)):479-489.
11. Thomas-Kaskel A.K., Zeiser R., Jochim R., Robbel C., Schultze-Seemann W., Waller C.F., et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006, 119(November (10)):2428-2434.
12. Hubert R.S., Vivanco I., Chen E., Rastegar S., Leong K., Mitchell S.C., et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 1999, 96(December (25)):14523-14528.
13. Challita-Eid P.M., Morrison K., Etessami S., An Z., Morrison K.J., Perez-Villar J.J., et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007, 67(June (12)):5798-5805.
14. Rodeberg D.A., Nuss R.A., Elsawa S.F., Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 2005, 11(June (12)):4545-4552.
15. Alves P.M., Faure O., Graff-Dubois S., Cornet S., Bolonakis I., Gross D.A., et al. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 2006, 55(December (12)):1515-1523.
16. Yang D., Holt G.E., Velders M.P., Kwon E.D., Kast W.M. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001, 61(August (15)):5857-5860.
17. Carroll M.W.R.N. Poxviruses as vectors for cancer immunotherapy. Cancer vaccines and immunotherapy 2000, 47-61. Cambridge University Press, Cambridge. P.L.B.P. Stern, M.W. Carroll (Eds.).
18. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992, 89(November (22)):10847-10851.
19. Sutter G., Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 1995, 84:195-200.
20. Ramirez J.C., Gherardi M.M., Rodriguez D., Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000, 74(August (16)):7651-7655.
21. Gomez C.E., Najera J.L., Krupa M., Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 2008, 8(April (2)):97-120.
22. Smith C.L., Dunbar P.R., Mirza F., Palmowski M.J., Shepherd D., Gilbert S.C., et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005, 113(January (2)):259-266.
23. Hodge J.W., Poole D.J., Aarts W.M., Gomez Yafal A., Gritz L., Schlom J. Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003, 63(November (22)):7942-7949.
24. Gherardi M.M., Ramirez J.C., Rodriguez D., Rodriguez J.R., Sano G., Zavala F., et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 1999, 162(June (11)):6724-6733.
25. Domingo-Gil E., Perez-Jimenez E., Ventoso I., Najera J.L., Esteban M. Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections. J Virol 2008, 82(January (1)):254-267.
26. Suttie A., Nyska A., Haseman J.K., Moser G.J., Hackett T.R., Goldsworthy T.L. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol 2003, 31(January-February (1)):31-38.
27. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996, 56(September (18)):4096-4102.
28. Kaplan-Lefko P.J., Chen T.M., Ittmann M.M., Barrios R.J., Ayala G.E., Huss W.J., et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003, 55(May (3)):219-237.
29. Garcia-Hernandez Mde L., Gray A., Hubby B., Kast W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007, 67(February (3)):1344-1351.
30. Garcia-Hernandez Mde L., Gray A., Hubby B., Klinger O.J., Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008, 68(February (3)):861-869.
31. Kim S., Lee J.B., Lee G.K., Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 2009, 69(June (9)):938-948.
32. Sanchez-Puig J.M., Sanchez L., Roy G., Blasco R. Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J 2004, 1:10.
33. Liu L., Chavan R., Feinberg M.B. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol 2008, 9:15.
34. Gasteiger G., Kastenmuller W., Ljapoci R., Sutter G., Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 2007, 81(November (21)):11925-11936.
35. Chahroudi A., Garber D.A., Reeves P., Liu L., Kalman D., Feinberg M.B. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 2006, 80(September (17)):8469-8481.
36. Drillien R., Spehner D., Hanau D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J Gen Virol 2004, 85(August (Pt 8)):2167-2175.
37. Guerra S., Najera J.L., Gonzalez J.M., Lopez-Fernandez L.A., Climent N., Gatell J.M., et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 2007, 81(August (16)):8707-8721.
38. Delaloye J., Roger T., Steiner-Tardivel Q.G., Le Roy D., Knaup Reymond M., Akira S., et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6 MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009, 5(June (6)):e1000480.
39. Gulley J.L., Arlen P.M., Tsang K.Y., Yokokawa J., Palena C., Poole D.J., et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008, 14(May (10)):3060-3069.
40. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005, 23(February (4)):720-731.
41. Irvine K.R., Chamberlain R.S., Shulman E.P., Surman D.R., Rosenberg S.A., Restifo N.P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997, 89(November (21)):1595-1601.
42. Hodge J.W., McLaughlin J.P., Kantor J.A., Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997, 15(April-May (6-7)):759-768.
43. Chen C.H., Wang T.L., Hung C.F., Pardoll D.M., Wu T.C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000, 18(April (19)):2015-2022.
44. Kaufman H.L., Wang W., Manola J., DiPaola R.S., Ko Y.J., Sweeney C., et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004, 22(June (11)):2122-2132.
45. McNeel D.G., Dunphy E.J., Davies J.G., Frye T.P., Johnson L.E., Staab M.J., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27(September (25)):4047-4054.
46. Miller A.M., Ozenci V., Kiessling R., Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005, 28(July-August (4)):389-395.
47. Amato R.J., Drury N., Naylor S., Jac J., Saxena S., Cao A., et al. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008, 31(July-August (6)):577-585.
48. Dreicer R., Stadler W.M., Ahmann F.R., Whiteside T., Bizouarne N., Acres B., et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009, 27(August (4)):379-386.
49. Kantoff P.W., Schuetz T.J., Blumenstein B.A., Glode L.M., Bilhartz D.L., Wyand M., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28(March (7)):1099-1105.